Eli Lilly的口服糖尿病药物在降低血糖和在后期试验中促进体重下降方面表现优于对手。 Eli Lilly's oral diabetes drug outperformed rivals in lowering blood sugar and promoting weight loss in late-stage trials.

艾利利利利的实验性口服糖尿病药物forglipron在两个晚期试验中显示出更好的血糖控制,与阿斯德拉泽内卡的Farxiga相比,A1C水平降低了1.7%,与胰岛素格拉相加降低了2.1%. Eli Lilly's experimental oral diabetes drug, orforglipron, showed superior blood sugar control in two late-stage trials, reducing A1C levels by up to 1.7% compared to AstraZeneca’s Farxiga and by 2.1% when added to insulin glargine. 该药物还导致40周以上不同剂量群体体重下降,心血管风险因素改善。 The drug also led to weight loss and improved cardiovascular risk factors across dose groups over 40 weeks. 先前的试验显示,它的业绩超过诺沃·诺迪斯克的Rybelsus。 Earlier trials showed it outperformed Novo Nordisk’s Rybelsus. 莉莉计划2026年提交该药物供糖尿病核准,到2025年底提交肥胖症治疗,预计2026年初将取得更多结果。 Lilly plans to submit the drug for diabetes approval in 2026 and for obesity treatment by year-end 2025, with additional results expected in early 2026.